Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jul;52(7):612-8.
doi: 10.1097/MLR.0000000000000143.

National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008

Maureen M Okam  1 , Shimon Shaykevich, Benjamin L Ebert, Alan M Zaslavsky, John Z Ayanian
Affiliations

National trends in hospitalizations for sickle cell disease in the United States following the FDA approval of hydroxyurea, 1998-2008

Maureen M Okam et al. Med Care. 2014 Jul.

Abstract

Background: Patients with sickle cell disease (SCD) can suffer frequent hospital admissions for painful vasoocclusive crises. Hydroxyurea was approved by the FDA in 1998 to decrease the morbidity of SCD, but nationwide hospitalizations for SCD in the United States since 1998 have not been evaluated. We hypothesized that the availability of hydroxyurea for SCD would be associated with a decrease in hospitalizations for SCD over time.

Objective: To assess trends in hospitalization and length-of-stay in hospital for SCD in the United States, 1998 through 2008.

Research design: Retrospective cohort study of SCD-related hospital discharges in the Nationwide Inpatient Sample of US hospital discharges.

Subjects: All discharges in the Nationwide Inpatient Sample associated with a principal diagnosis of SCD in blacks, 1998 through 2008.

Measures: Trends in hospitalization rates and average length-of-stay in hospital for SCD.

Results: We found 216 (95% confidence interval, 173.3-258.7) SCD-related hospitalizations per 100,000 US blacks in 1998 and 178.4 (95% confidence interval, 144.2-212.5) in 2008, but no consistent yearly decrease, 1998 through 2008 (P=0.30). Conversely, the length-of-stay in hospital in 1998 was 5.38 days and in 2008 was 5.18 days, an absolute change of 0.2 days and a downward trend that was statistically significant.

Conclusions: Between 1998 and 2008, there was not a steady decrease in hospitalization rates for the population of SCD in the United States. On the contrary, there was a decline in length-of-stay in hospital over this time. Hydroxyurea underuse is well documented. Efforts to increase hydroxyurea use may help to reduce hospitalization rates.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Trends in Hospitalization Rates for Sickle Cell Disease per 100,000 Black Population in the United States, 1998 to 2008. (Trend, p = 0.30)
Figure 2
Figure 2
Trends in Hospitalization Rates for Sickle Cell Disease in Adults and Children per 100,000 Black Population in the United States, 1998 to 2008. (trend in adults, p = 0.30; trend in children, p = 0.34)
Figure 3
Figure 3
Trends in Hospital Length of Stay (LOS) for Sickle Cell Disease in the United States, 1998 to 2008.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Brousseau DC, Panepinto JA, Nimmer M, et al. The number of people with sickle-cell disease in the United States: national and state estimates. American journal of hematology. 2010;85:77–78. - PubMed
    1. Hassell KL. Population estimates of sickle cell disease in the U.S. American journal of preventive medicine. 2010;38:S512–S521. - PubMed
    1. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease. Life expectancy and risk factors for early death. The New England journal of medicine. 1994;330:1639–1644. - PubMed
    1. Shankar SM, Arbogast PG, Mitchel E, et al. Medical care utilization and mortality in sickle cell disease: a population-based study. American journal of hematology. 2005;80:262–270. - PubMed
    1. Mozzarelli A, Hofrichter J, Eaton WA. Delay time of hemoglobin S polymerization prevents most cells from sickling in vivo. Science. 1987;237:500–506. - PubMed

Publication types